课题基金 / 基金详情

INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES

INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES
干扰素 A——糖尿病蜜月期的延长或持久
批准号：
6121138
负责人：
STALEY armstrong BROD
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6121138
关键词：
clinical research clinical trial phase I diabetes mellitus therapy human subject human therapy evaluation immunotherapy insulin dependent diabetes mellitus interferon alpha oral administration pancreatic islet function

项目摘要

项目成果

STALEY armstrong BROD的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项I-II期临床试验，研究了胰岛素依赖型糖尿病（IDDM）（一种自身免疫性疾病）的口服干扰素- α (IFN-a)。研究IFN-a对IDDM患者免疫功能和β细胞功能及破坏的影响。新诊断为IDDM的受试者将被纳入长达12个月的治疗期。通过摄入IFN-a确定临床改善或免疫抑制，可能会导致以临床疾病持续改善为主要结局的安慰剂对照II-III期试验。
英文摘要
This is a phase I-II trial of ingested interferon-alpha (IFN-a) in insulin dependent diabetes mellitus (IDDM), an autoimmune disease. It will study the effect of IFN-a on immune function and Beta cell function and destruction in IDDM. Subjects with newly diagnosed IDDM will be enrolled for a treatment period of up to 12 months. Establishment of clinical improvement or immunosuppression with ingested IFN-a may lead to a placebo-controlled phase II-III trial with persistent improvement in clinical disease as a primary outcome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES
海外基金